Salt Lake City—Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing treatments for hematological diseases, unveiled its new headquarters Friday at 3900 North Traverse Blvd in Lehi, Utah. To inaugurate the facility, Chief Executive Officer and Founder David J. Bearss, Ph.D. will be joined by leadership from Tolero’s parent company, Sumitomo Dainippon Pharma Co., Ltd., representatives from the Leukemia and Lymphoma Society, and dignitaries from state and local governments for a ribbon-cutting ceremony at 10:00 a.m. local time.
“On behalf of all our employees, I am pleased to be a corporate citizen of Lehi and proud to call Utah our home,” said Dr. Bearss. “Opening a new headquarters and cutting-edge research facility underscores Tolero’s commitment to science that may make a difference in the lives of cancer patients across the country, in the state of Utah, and here in our own backyard.”
Tolero has been headquartered in Lehi since its inception in 2011. Tolero’s new facility includes a research laboratory where the company will continue to advance its pipeline of potential treatments for acute myeloid leukemia, and other cancers.